Mechanistically, we discovered that CHAF1B could activate the PI3K/Akt/HIF-1α signaling pathway, thereby enhancing the intrinsic resistance of HCC cells to sorafenib. This evidence concerns the gene CHAF1B and hepatocellular carcinoma.